Paolo Tarantino: A Special Collection for ADCs in Breast Oncology for Nature Portfolio

Paolo Tarantino shared on LinkedIn:

“The field of ADCs is still at its dawn.

Many challenges persist, yet major innovations are coming to improve upon earlier ADC generations and achieve the goal of the magic bullet to treat cancer.

Tess O’Meara and I are editing a Special Collection for ADCs in Breast Oncology for Nature Portfolio.

If you’re working at an ADC paper, please consider submission here.”

Innovations and challenges in antibody-drug conjugates for breast cancer | Nature Portfolio

Editors: Paolo Tarantino and Tess A. O’Meara

Source: Paolo Tarantino/LinkedIn 

More posts featuring Paolo Tarantino on oncodaily.com

Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.

His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a  publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.